Affiliation:
1. Zhongnan Hospital of Wuhan University
Abstract
Abstract
Purpose
Tumor associated macrophages (TAM) influence colorectal cancer (CRC) development, and their clinical significance has been widely established. We intend to depict a full macrophage landscape in order to increase our understanding of CRC heterogeneity and give improved precision medicine techniques.
Methods
Use Seurat and Cellchat to conduct single cell analysis on GSE178341 to determine the interaction between cells and understand the influence of core cell subsets on immune response. SsGSEA was used to quantify the immune related cells of TCGA patients and further cluster them into subtypes. The effectiveness of combined COX and LASSO, SPP1 TAM characteristics in predicting prognosis was validated in several GEO datasets.
Then, Cell line culture and Quantitative real-time PCR were used to validate the hub genes of SPP1 TAM features.
Results and Conclusion
To summarize, we built a more comprehensive macrophage atlas to highlight the wide range and heterogeneity of macrophages present in people at various MMR stages. SPP1 TAM is not only enriched in dMMR patients, but also shows two characteristics of immune response, which may explain the reason why some dMMR patients have poor response to immunotherapy. The prognosis model constructed by Hub DEG SPP1 related to it has different responses to immune response and chemotherapy drugs, which provides new clues to inhibit the potential efficacy of SPP1 TAM.
Publisher
Research Square Platform LLC
Reference44 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians;Bray F,2018
2. Worldwide variations in colorectal cancer;Center M;CA: a cancer journal for clinicians,2009
3. Intratumoral immunotherapy: using the tumor as the remedy;Marabelle A;Annals of oncology: official journal of the European Society for Medical Oncology,2017
4. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer;Yang Z;Frontiers in immunology,2022
5. Top 10 Challenges in Cancer Immunotherapy;Hegde P;Immunity,2020